TUCATINIB
Information current as at: 1 June 2026
The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.
Submission Details
- Brand name:
-
- Tukysa®
- Form and strength:
- Please search for and view the medicine's Public Summary Document (PSD) for more information
- Condition/indication:
(therapeutic use) -
- Breast cancer
- Listing requested:
- Please see PSD for more information
- Funding program:
- Please see PSD for more information
- Request authority level:
- Please see PSD for more information
- PBAC submission type:
- New PBS listing (–)
- Comment:
- --
- Submission sponsor:
- PFIZER AUSTRALIA PTY LTD
- Other PBAC consideration:
Progress Details
-
Submission received for: - November 2025 PBAC meeting
-
Opportunity for consumer comment: - Open 30/07/2025 and close 24/09/2025 (see PBS Website)
-
PBAC meeting: - Held on 05/11/2025
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID: a1128
Page last updated: 31 March 2026